Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCM332
- Development stage
- Phase 1
- Lead developer
- Shanghai Bocimed Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BCM332 is a small molecule, highly selective inhibitor of the voltage-gated sodium channel Nav1.6 (SCN8A), developed by Shanghai Bozhi Yanshen Pharmaceutical Technology Co., Ltd. It is primarily indicated for the treatment of epilepsy, specifically focal seizures. By selectively blocking Nav1.6, which is a major mediator of neuronal firing in the central nervous system, BCM332 aims to provide potent anti-seizure activity with an improved safety profile compared to non-selective sodium channel blockers. The drug is currently undergoing Phase II clinical evaluation in China.
02
Targets
SCN8A (NaV1.6)
Beyond the preview
Go deeper on BCM332.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCM332.